UNSPSC 51271617: Rodocaine

This classification denotes an anesthetic agent with the molecular formula C18H25ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9W0Z08C70V, chemically known as 1h-pyrindine-1-propanamide, n-(2-chloro-6-methylphenyl)octahydro- trans- but generally known as rodocaine, which bears US NIH Compound Identifier 71441. European Medicines Agency schedules Rodocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10354MIG. The term RODOCAINE is an International Non-Proprietary Name.

UNSPSC 51271617 Rodocaine is a Commodity code covering local anesthetic pharmaceutical products supplied through state and local cooperative purchasing vehicles and direct government procurement. The code sees activity primarily through multistate cooperative purchasing alliances that aggregate demand across participating state agencies, counties, municipalities, and health systems, with vendors supplying pharmaceuticals through authorized wholesale distribution channels rather than directly to end-use facilities. State and local governments use this code to procure generic and branded pharmaceutical products—including topical anesthetics, injectable anesthetics, and related OTC formulations—with contracting structured around National Drug Code (NDC) specifications, pricing models, and compliance with FDA requirements and Drug Supply Chain Security Act (DSCSA) standards. Issuing bodies are typically state departments of administration or procurement offices administering cooperative purchasing agreements on behalf of multiple participating jurisdictions; the recent activity shows Minnesota's multistate cooperative model serving members across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) for Generic Multi Source Pharmaceuticals and OTC Products with a response deadline of March 26, 2026 and contract effectiveness of July 1, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards structured to support participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Evaluation weighs price competitiveness at 75 percent, fixed pricing and administrative compliance at 10–15 percent combined, EDI capability at 5 percent, and agreement to a 3 percent administrative fee at 5 percent. Vendors must carry $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability; maintain relationships with at least two authorized wholesalers with chargeback capability; and certify cGMP and DSCSA compliance. The RFP does not designate set-aside restrictions and reserves MMCAP's right to make sole, dual, or multi-awards based on therapeutic considerations and member needs.